Opinion|Videos|December 5, 2025
Therapeutic Potential of TYK2 Inhibition in Psoriasis
Explore the distinct role of TIC-2 in psoriasis and how selective inhibition offers targeted treatment advantages over traditional JAK inhibitors.
Advertisement
Episodes in this series
TYK2 is a member of the JAK family but is structurally distinct. Can you elaborate on the mechanistic role of TYK2 in psoriasis pathophysiology?
Advertisement
Related to this article
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Advertisement
Advertisement
Trending on HCPLive
1
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
2
Conservative Therapy in Fibrillary GN: A Four-Drug Kidney-Protective Approach
3
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5